Charles River Labs (CRL) Receives a Rating Update from a Top Analyst

By Austin Angelo

Jefferies analyst David Windley reiterated a Buy rating on Charles River Labs (CRLResearch Report) yesterday and set a price target of $162. The company’s shares closed yesterday at $139.12, close to its 52-week high of $139.91.

According to, Windley is a top 25 analyst with an average return of 20.7% and a 77.2% success rate. Windley covers the Services sector, focusing on stocks such as Centene Corp, Cigna Corp, and Anthem Inc.

Currently, the analyst consensus on Charles River Labs is a Moderate Buy with an average price target of $142.57, which is a 2.5% upside from current levels. In a report released yesterday, Robert W. Baird also maintained a Buy rating on the stock with a $155 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $139.91 and a one-year low of $101.58. Currently, Charles River Labs has an average volume of 384.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions.